Form 4: Stryker Corp Director Lisa Skeete Tatum Reports Acquisition of 653 Restricted Stock Units

Director Lisa Skeete Tatum acquired 653 Restricted Stock Units (RSUs) of Stryker Corp on May 9, 2024, which will vest on the earlier of the 2025 Annual Meeting or May 9, 2025.

Summary

• On May 9, 2024, Lisa Skeete Tatum, a director of Stryker Corp, acquired 653 Restricted Stock Units (RSUs).
• The RSUs were granted at a price of $0.
• Each RSU represents a contingent right to receive one share of Stryker Common Stock.
• The RSUs will vest 100% on the earlier of the date of the 2025 Annual Meeting of Shareholders or May 9, 2025.
• Following the transaction, Lisa Skeete Tatum beneficially owns 3,883 shares of Stryker Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of RSUs by a director is generally a good sign, indicating confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the RSUs is contingent upon the earlier of the 2025 Annual Meeting of Shareholders or May 9, 2025, suggesting a continued commitment by the director to the company's long-term performance.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency regarding their transactions in the company's securities. This particular filing indicates a grant of restricted stock units, a common form of executive compensation in the medical technology industry.

Comparison to Industry Standards

• Stock grants are a common form of compensation for directors in publicly traded companies, including those in the medical device industry like Medtronic, Johnson & Johnson, and Boston Scientific.
• The size of the grant is typical for director compensation, aligning with industry practices to incentivize and retain board members.

Stakeholder Impact

• The acquisition of RSUs by a director can positively influence shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates